Recent News

• 06.03.2026 - Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
• 06.03.2026 - Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
• 06.03.2026 - Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
• 05.14.2026 - Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
• 05.14.2026 - Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
• 05.14.2026 - Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
• 05.14.2026 - Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
• 05.14.2026 - Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
• 05.04.2026 - Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
• 05.04.2026 - Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Recent Filings

• 06.04.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 06.03.2026 - 8-K Current report
• 06.03.2026 - EX-99.1 EX-99.1
• 06.01.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.14.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.14.2026 - EX-99.1 EX-99.1
• 05.14.2026 - EX-99.1 EX-99.1
• 05.14.2026 - 8-K Current report
• 05.14.2026 - 8-K Current report